|
Baseline Patient Characteristics (ITT Population) |
|||
| Lumiracoxib 100 mg o.d. (n = 755) |
Lumiracoxib 100 mg b.i.d. (n = 1,519) |
Celecoxib 200 mg o.d. (n = 758) |
|
|
|
|||
| Age (years), mean ± SD |
62.9 ± 10.25 |
62.2 ± 10.02 |
62.7 ± 10.00 |
| Females, n (%) |
541 (71.7) |
1081 (71.2) |
531 (70.1) |
| BMI (kg/m2), mean ± SD |
29.5 ± 6.41 |
29.7 ± 6.34 |
29.8 ± 6.33 |
| Race, n (%) |
|||
| White/Caucasian |
712 (94.3) |
1450 (95.5) |
731 (96.4) |
| Black/African American |
22 (2.9) |
45 (3.0) |
13 (1.7) |
| Hispanic |
10 (1.3) |
8 (0.5) |
11 (1.5) |
| Other† |
11 (1.5) |
16 (1.1) |
3 (0.4) |
| Disease duration (years), mean ± SD |
7.9 ± 7.73 |
7.6 ± 7.79 |
7.5 ± 7.62 |
| Target joint, n (%) |
|||
| Hip |
58 (7.7) |
122 (8.0) |
59 (7.8) |
| Knee |
376 (49.8) |
743 (48.9) |
350 (46.2) |
| Hand |
159 (21.1) |
301 (19.8) |
166 (21.9) |
| Spine |
162 (21.5) |
353 (23.2) |
183 (24.1) |
| OA pain, n (%) |
|||
| Mild |
48 (6.4) |
102 (6.7) |
49 (6.5) |
| Moderate |
363 (48.1) |
704 (46.3) |
346 (45.6) |
| Severe |
343 (45.4) |
712 (46.9) |
361 (47.6) |
| Extreme |
1 (0.1) |
1 (0.1) |
2 (0.3) |
| Patient's global assessment of disease activity, n (%) |
|||
| Very good |
2 (0.3) |
8 (0.5) |
4 (0.5) |
| Good |
94 (12.5) |
167 (11.0) |
78 (10.3) |
| Fair |
340 (45.0) |
711 (46.8) |
360 (47.5) |
| Poor |
296 (39.2) |
581 (38.2) |
287 (37.9) |
| Very poor |
23 (3.0) |
51 (3.4) |
29 (3.8) |
| Physician's global assessment of disease activity, n (%) |
|||
| Very good |
1 (0.1) |
0 (0.0) |
2 (0.3) |
| Good |
51 (6.8) |
85 (5.6) |
45 (5.9) |
| Fair |
371 (49.1) |
784 (51.6) |
373 (49.2) |
| Poor |
317 (42.0) |
618 (40.7) |
324 (42.7) |
| Very poor |
14 (1.9) |
31 (2.0) |
12 (1.6) |
| Short Arthritis assessment Scale (SAS) total score, mean ± SD |
22.4 ± 7.81 |
22.1 ± 7.61 |
22.3 ± 7.86 |
|
o.d. = once daily; b.i.d. = twice daily; BMI = body mass index; ITT = intention-to-treat; SD = standard deviation; †Japanese, other Asian or Pacific Islander or other. | |||
Fleischmann et al. BMC Musculoskeletal Disorders 2008 9:32 doi:10.1186/1471-2474-9-32 |
|||